PURPOSE: Intracranial clear cell meningioma (CCM) represents a rare and potentially more aggressive subgroup of meningioma that is observed more frequently in children and adolescents. Despite its characterization as a histological entity, there is little evidence identifying tumorigenic etiologies. Recently, a novel mutation in SMARCE1, encoding a subunit of the SWI/SNF chromatin remodeling complex, was identified in a cohort of spinal CCMs. To date, no intracranial CCM has been subjected to analysis. METHODS: We report the case of an isolated intracranial CCM in a 14-year-old girl. Gross total resection was achieved following a two-stage approach with no evidence of tumor recurrence 8 months following presentation. RESULTS: Exon sequencing identified a germline mutation in SMARCE1, which was also present in tumor DNA. Extensive literature review confirmed our study is the first to seek and report a genetic anomaly for childhood intracranial CCMs outside of the NF2 gene locus, and the first to make an association between a germline SMARCE1 mutation and childhood intracranial CCMs. CONCLUSIONS: Together with the previous description of SMARCE1 mutations in spinal CCMs, our report suggests that SMARCE1 aberrations may be implicated in establishing a clear cell histology irrespective of meningioma location. We would advocate that, where feasible, genetic sequencing is performed on future new cases of childhood neuraxial CCMs and includes interrogation of the SMARCE1 gene.
PURPOSE: Intracranial clear cell meningioma (CCM) represents a rare and potentially more aggressive subgroup of meningioma that is observed more frequently in children and adolescents. Despite its characterization as a histological entity, there is little evidence identifying tumorigenic etiologies. Recently, a novel mutation in SMARCE1, encoding a subunit of the SWI/SNF chromatin remodeling complex, was identified in a cohort of spinal CCMs. To date, no intracranial CCM has been subjected to analysis. METHODS: We report the case of an isolated intracranial CCM in a 14-year-old girl. Gross total resection was achieved following a two-stage approach with no evidence of tumor recurrence 8 months following presentation. RESULTS: Exon sequencing identified a germline mutation in SMARCE1, which was also present in tumor DNA. Extensive literature review confirmed our study is the first to seek and report a genetic anomaly for childhood intracranial CCMs outside of the NF2 gene locus, and the first to make an association between a germline SMARCE1 mutation and childhood intracranial CCMs. CONCLUSIONS: Together with the previous description of SMARCE1 mutations in spinal CCMs, our report suggests that SMARCE1 aberrations may be implicated in establishing a clear cell histology irrespective of meningioma location. We would advocate that, where feasible, genetic sequencing is performed on future new cases of childhood neuraxial CCMs and includes interrogation of the SMARCE1 gene.
Authors: Miriam J Smith; Jenny E Higgs; Naomi L Bowers; Dorothy Halliday; Joan Paterson; James Gillespie; Susan M Huson; Simon R Freeman; Simon Lloyd; Scott A Rutherford; Andrew T King; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans Journal: J Med Genet Date: 2011-01-28 Impact factor: 6.318
Authors: Yohan Lee; Jason Liu; Shilpa Patel; Timothy Cloughesy; Albert Lai; Haumith Farooqi; David Seligson; Jun Dong; Linda Liau; Donald Becker; Paul Mischel; Soheil Shams; Stanley Nelson Journal: Brain Pathol Date: 2009-11-20 Impact factor: 6.508
Authors: Evangelos Kiskinis; Juana M García-Pedrero; M Angeles Villaronga; Malcolm G Parker; Borja Belandia Journal: Breast Cancer Res Treat Date: 2006-03-15 Impact factor: 4.872
Authors: R Wellenreuther; J A Kraus; D Lenartz; A G Menon; J Schramm; D N Louis; V Ramesh; J F Gusella; O D Wiestler; A von Deimling Journal: Am J Pathol Date: 1995-04 Impact factor: 4.307
Authors: Pablo Miranda; Juan Antonio Simal; Manuel Vila; Miguel Hernández; Francisco Menor; José Andrés Alvarez-Garijo Journal: Childs Nerv Syst Date: 2008-11-22 Impact factor: 1.475
Authors: Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2021-03-14 Impact factor: 4.553
Authors: Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Mohamed H Abdel-Rahman; Klarke M Sample; Robert Pilarski; Tomas Walsh; Timothy Grosel; Daniel Kinnamon; Getachew Boru; James B Massengill; Lynn Schoenfield; Ben Kelly; David Gordon; Peter Johansson; Meghan J DeBenedictis; Arun Singh; Silvia Casadei; Frederick H Davidorf; Peter White; Andrew W Stacey; James Scarth; Ellie Fewings; Marc Tischkowitz; Mary-Claire King; Nicholas K Hayward; Colleen M Cebulla Journal: Ophthalmology Date: 2019-11-18 Impact factor: 12.079
Authors: Elmar Kirches; Felix Sahm; Andrey Korshunov; Stefan M Pfister; Christian Mawrin; Christina Bluecher; Natalie Waldt; Siegfried Kropf; Daniel Schrimpf; Philipp Sievers; Damian Stichel; Ulrich Schüller; Jens Schittenhelm; Markus J Riemenschneider; Matthias A Karajannis; Arie Perry; Torsten Pietsch; Svenja Boekhoff; David Capper; Katja Beck; Nagarajan Paramasivam; Matthias Schlesner; Priscilla K Brastianos; Hermann L Müller Journal: Acta Neuropathol Date: 2021-09-08 Impact factor: 17.088
Authors: E H Gerkes; J M Fock; W F A den Dunnen; M J van Belzen; C A van der Lans; E W Hoving; I E Fakkert; M J Smith; D G Evans; M J W Olderode-Berends Journal: Neurogenetics Date: 2016-01-23 Impact factor: 2.660